Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a globally active specialist for radioactive applications in industry and medicine, achieved third-quarter sales of 12.8 million EUR despite the sale of its blood radiation systems business, and thus increased its cumulative sales as of 30 September 2007 by 3.4 million EUR or 9.5% over the same period of last year. The EBIT rose to 4.2 million EUR in the same period, which corresponds to an increase of 4%. The surplus decreased by 0.8 million EUR to 1.3 million EUR due to special effects from the corporate tax reform. Without this non-monetary special burden arising from re-evaluation of losses carried forward, the result would be 0.68 EUR per share, which is slightly above the level of last year.
Sales in all segments increased over the respective figures for the same nine-month period of last year. The Radiopharmaceuticals segment once again showed the strongest growth in sales over last year, with an increase of 48% to 5.4 million EUR. Sales in the Therapy segment grew by 8% to 14.8 million EUR. Sales in the Industry segment showed only a slight nominal increase of 3% to 19 million EUR. Making allowances the unfavorable development in the exchange rate between the euro and the US dollar, however, growth in this segment amounted to 10%.
Regarding the overall profit for 2007, the Board continues to forecast 0.90 EUR per share before special or one-time effects. Taking effects from the corporate tax reform into account, a result of 0.63 EUR per share is expected.
For 2008, the Board anticipates further growth in sales and profit. If the average exchange rate of the US dollar to the euro does not exceed 1.40, the overall surplus for next year is expected to increase by approximately 10% to 1.00 EUR per share.
Further details on business development in the third quarter are contained in the Quarterly Report to be released today
Sales in all segments increased over the respective figures for the same nine-month period of last year. The Radiopharmaceuticals segment once again showed the strongest growth in sales over last year, with an increase of 48% to 5.4 million EUR. Sales in the Therapy segment grew by 8% to 14.8 million EUR. Sales in the Industry segment showed only a slight nominal increase of 3% to 19 million EUR. Making allowances the unfavorable development in the exchange rate between the euro and the US dollar, however, growth in this segment amounted to 10%.
Regarding the overall profit for 2007, the Board continues to forecast 0.90 EUR per share before special or one-time effects. Taking effects from the corporate tax reform into account, a result of 0.63 EUR per share is expected.
For 2008, the Board anticipates further growth in sales and profit. If the average exchange rate of the US dollar to the euro does not exceed 1.40, the overall surplus for next year is expected to increase by approximately 10% to 1.00 EUR per share.
Further details on business development in the third quarter are contained in the Quarterly Report to be released today
